S&CO Inc. Buys Shares of 111,284 Elanco Animal Health Incorporated $ELAN

Key Points

• S&CO Inc. purchased 111,284 Elanco shares worth approximately $2.74 million, while institutional investors and hedge funds collectively own 97.48% of the company.
• Wall Street remains broadly positive, with a consensus “Moderate Buy” rating and an average price target of $29.09; several analysts recently raised their targets to as high as $33.
• Elanco exceeded quarterly expectations with adjusted EPS of $0.34 versus the $0.27 estimate and revenue of $1.37 billion, up 10.2% year over year. Two directors also bought shares recently, contributing to 19,200 insider-purchased shares over the past quarter.

S&CO Inc. purchased a new stake in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 111,284 shares of the company's stock, valued at approximately $2,738,000.

Several other large investors have also modified their holdings of ELAN. NewEdge Advisors LLC raised its position in shares of Elanco Animal Health by 133.7% during the 4th quarter. NewEdge Advisors LLC now owns 1,096 shares of the company's stock worth $25,000 after purchasing an additional 627 shares during the last quarter. Root Financial Partners LLC grew its holdings in Elanco Animal Health by 50.7% during the 4th quarter. Root Financial Partners LLC now owns 1,759 shares of the company's stock valued at $40,000 after buying an additional 592 shares during the last quarter. Uniplan Investment Counsel Inc. acquired a new stake in Elanco Animal Health during the 4th quarter valued at $41,000. Torren Management LLC purchased a new position in Elanco Animal Health during the fourth quarter worth $46,000. Finally, Bessemer Group Inc. increased its position in Elanco Animal Health by 33.2% during the first quarter. Bessemer Group Inc. now owns 2,105 shares of the company's stock worth $50,000 after buying an additional 525 shares in the last quarter. 97.48% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on ELAN shares. TD Cowen upped their price objective on Elanco Animal Health from $31.00 to $32.00 and gave the company a "buy" rating in a research report on Thursday, June 18th. KeyCorp lifted their price objective on Elanco Animal Health from $29.00 to $30.00 and gave the stock an "overweight" rating in a research report on Thursday, August 6th. Citigroup boosted their target price on shares of Elanco Animal Health from $30.00 to $31.00 and gave the company a "buy" rating in a research note on Thursday, May 7th. UBS Group upped their target price on shares of Elanco Animal Health from $31.00 to $33.00 and gave the company a "buy" rating in a report on Thursday, August 6th. Finally, JPMorgan Chase & Co. raised their price target on shares of Elanco Animal Health from $28.00 to $30.00 and gave the stock an "overweight" rating in a research note on Thursday, May 7th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $29.09.

Elanco Animal Health Trading Up 5.0%

Shares of Elanco Animal Health stock opened at $23.64 on Friday. Elanco Animal Health Incorporated has a fifty-two week low of $17.11 and a fifty-two week high of $27.98. The business's fifty day moving average is $24.56 and its two-hundred day moving average is $24.02. The company has a quick ratio of 1.10, a current ratio of 2.05 and a debt-to-equity ratio of 0.58. The firm has a market cap of $11.81 billion, a PE ratio of -57.65, a P/E/G ratio of 1.42 and a beta of 1.67.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $0.34 EPS for the quarter, beating analysts' consensus estimates of $0.27 by $0.07. Elanco Animal Health had a positive return on equity of 8.13% and a negative net margin of 3.96%.The business had revenue of $1.37 billion during the quarter, compared to the consensus estimate of $1.31 billion. During the same quarter in the previous year, the business earned $0.26 earnings per share. The business's revenue for the quarter was up 10.2% on a year-over-year basis. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. Analysts anticipate that Elanco Animal Health Incorporated will post 1.12 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Paul Herendeen bought 10,000 shares of the business's stock in a transaction that occurred on Friday, August 7th. The shares were acquired at an average cost of $23.68 per share, with a total value of $236,800.00. Following the transaction, the director owned 111,687 shares of the company's stock, valued at $2,644,748.16. This represents a 9.83% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Michael J. Harrington bought 5,000 shares of Elanco Animal Health stock in a transaction that occurred on Wednesday, August 12th. The stock was purchased at an average price of $21.82 per share, for a total transaction of $109,100.00. Following the acquisition, the director directly owned 131,451 shares of the company's stock, valued at $2,868,260.82. The trade was a 3.95% increase in their position. The SEC filing for this purchase provides additional information. Insiders have purchased a total of 19,200 shares of company stock valued at $442,836 over the last quarter. Company insiders own 1.14% of the company's stock.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco's portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.

Want to see what other hedge funds are holding ELAN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elanco Animal Health Incorporated (NYSE:ELAN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source